Skip to content

Clinical trials

Gastrointestinal Stromal Tumors trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Gastrointestinal Stromal Tumors Country / region: United States Clear all

137 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20009
20014
20026
20034
20043
20056
20063
20079
20087
20096
20105
20117
20125
20138
20142
20155
20163
20175
20184
20193
20202
20214
20225
20234
20244
20255
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed79
Terminated24
Recruiting18
Active, not recruiting10
Unknown status2
Not yet recruiting1
Suspended1
Available1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)22
Novartis Pharmaceuticals12
Deciphera Pharmaceuticals, LLC7
M.D. Anderson Cancer Center6
Pfizer5
Stanford University5
Memorial Sloan Kettering Cancer Center4
Northwestern University4
Blueprint Medicines Corporation3
Cogent Biosciences, Inc.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Gastrointestinal Stromal Tumors137
Stomach Neoplasms28
Sarcoma25
Pancreatic Neoplasms21
Colonic Neoplasms18
Esophageal Neoplasms17
Breast Neoplasms15
Gallbladder Neoplasms15
Carcinoma, Hepatocellular14
Carcinoma, Non-Small-Cell Lung14

Trials

Showing 1 to 25 of 137. Each trial links to its page on Pharma Observatory.

37 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.